International Cancer Vaccine
SymposiumIn Washington DC 2006
February 5-7, 2006 North Bethesda
Marriott Hotel, Bethesda, Maryland, USA
MONDAY 6 FEBRUARY 2006
SESSION 1: chaired by Dr. Jeffrey
Schlom, National Cancer Institute, NIH, USA
| 10:00 |
A Novel DNA-based Vaccines for Cancer Therapy
Dr. Ralph A. Reisfeld, The Scripps Research Institute, USA
|
| 10:30 |
Design and Development of Recombinant Vaccines for the
Therapy of Carcinomas Dr. Jeffrey Schlom, National
Cancer Institute, NIH, USA |
| 11:00 |
Immunotherapy of Established Papilloma Virus-Induced
(pre-)Malignant Lesions in Mice, Rabbits and Patients
Professor Cornelis Melief, University Hospital Leiden,
the Netherlands |
| 11:30 |
Design and Optimization of Peptide-Based Vaccines for
Cancer Dr. Esteban Celis, Louisiana State University
Health Science Center, USA |
SPECIAL REMARKS:
| 13:00 |
Current Research and Drug Discovery in a New Era
Dr. John E. Niederhuber, Deputy Director, National
Cancer Institute, NIH, USA |
SESSION 2: chaired by Dr. Tyler
Curiel, Tulane Medical School, USA
| 13:30 |
Tumour Cell-Dendritic Cell Fusion Vaccine Dr.
David Avigan, Beth Israel Deaconess Medical Center, USA |
| 14:00 |
Overcoming Negative Regulation to Enhance Cancer Vaccines
and Immunosurveillance Dr.
Jay Berzofsky, National Cancer Institute, NIH, USA |
| 14:30 |
Regulatory T Cell Depletion in Cancer: Immunologic and
Clinical Correlates Dr.
Tyler Curiel, Tulane Medical School, USA |
| 15:00 |
Autoimmunity and Vaccination in Melanoma Dr.
Jeffrey S. Weber, USC/Norris Comprehensive Cancer Institute,
USA |
SESSION 3: chaired by Dr. Dean Mann,
University of Maryland Baltimore, USA
| 15:50 |
Prevention of HPV Infection and Cervical Cancer
Dr .Douglas Lowy, National Cancer
Institute, NIH, USA |
| 16:20 |
Innate Immunity in Cancer and Hematopoietic Cell Transplantation
Dr. Jeffrey S. Miller, University
of Minnesota, USA |
| 16:50 |
Antigens Targeted in the Successful Immunosurveillance
of Tumor Progression are Candidates for Prophylactic Cancer Vaccines
Dr. Olivera “Olja” J. Finn, University
of Pittsburgh, USA |
TUESDAY 7 FEBRUARY 2006
SESSION 4:
chaired by Dr. Ralph A. Reisfeld, The Scripps Research
Institute, USA
| 8:30 |
Optimisation of Cancer Vaccines for Therapy of The Common
Solid Tumours
Professor
Angus Dalgliesh, St. George’s University of London, United Kingdom |
| 9:00 |
Vaccines for Prostate Cancer ? a Translational Journey
from Conception to Phase III Clinical Studies
Dr.
James L. Gulley, National Cancer Institute, NIH, USA |
| 9:30 |
Heat-Shock Proteins: Immunobiology and Use in Cancer
Vaccines
Professor Giorgio
Parmiani, Istituto Nazionale Tumori, Milano, Italy |
| |
|
SESSION 5:
chaired by Dr. Ronald Levy, Stanford University School
of Medicine, USA
| 10:20 |
Therapeutic Vaccination for Lymphoid Malignancy
Dr. Ronald Levy, Stanford University
School of Medicine, USA |
| 10:50 |
Dendritic Cell Vaccination and Amplification Strategies
Professor Gerold Schuler,
University Hospital of Erlangen, Germany |
| 11:20 |
Imiquimod-Induced Regression of Cutaneous Neoplasms:
Cellular and Molecular Mechanisms Professor
Georg Stingl, University of Vienna Medical School, Austria |
| 11:50 |
Dendritic Cell as Therapeutic Vaccines in Cancer
Dr. Karoline Palucka, Baylor Institute
for Immunology Research, USA |
SESSION 6:
chaired by Dr. Elizabeth M. Jaffe, Johns Hopkins, USA
| 13:20 |
Tipping the Immune System Balance in Favor of Effective
Anti-Cancer Interventions
Dr.
Elizabeth M. Jaffe, Johns Hopkins, USA |
| 13:50 |
Recent Progress in Human Cancer Immunotherapy
Dr. Steven A. Rosenberg, National
Cancer Institute, NIH, USA |
| 14:20 |
Checkpoint Blockade in Cancer Immunotherapy
Dr. James P. Allison, Howard Hughes
Medical Institute/Memorial Sloan-Kettering Cancer Center, USA |
SESSION 7:
chaired by Dr. Crystal L. Mackall, National Cancer Institute,
NIH, USA
| 15:10 |
The Present Status of Active Specific Immunotherapy
with Canvaxin Whole-Cell Vaccine after Resection of Metastatic
Melanoma
Dr. Donald
L. Morton, John Wayne Cancer Institute, USA |
| 15:40 |
Evaluation of Antigens for Vaccination Against Prostate
Cancer
Professor Peter
Rieber, Technical University Dresden, Germany |
| 16:10 |
Contrasting IL-2 and IL-7 in Cancer Immunotherapy and
Immune Reconstitution
Dr.
Crystal L. Mackall, National Cancer Institute, NIH, USA |
|
